These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24891343)

  • 1. Neratinib Graduates to I-SPY 3.
    Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
    [No Abstract]   [Full Text] [Related]  

  • 2. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
    Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
    Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib Approved for HER2+ Breast Cancer.
    Cancer Discov; 2017 Sep; 7(9):OF1. PubMed ID: 28778899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib (Nerlynx) for HER2-positive breast cancer.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
    [No Abstract]   [Full Text] [Related]  

  • 9. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
    Campos SM
    Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
    [No Abstract]   [Full Text] [Related]  

  • 12. TEACH: Tykerb evaluation after chemotherapy.
    Moy B; Goss PE
    Clin Breast Cancer; 2007 Feb; 7(6):489-92. PubMed ID: 17386127
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quo vadis with targeted drugs in the 21st century?
    Bergh J
    J Clin Oncol; 2009 Jan; 27(1):2-5. PubMed ID: 19047306
    [No Abstract]   [Full Text] [Related]  

  • 16. Neratinib and capecitabine for breast cancer brain metastases.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e197. PubMed ID: 30910514
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 18. Breast Cancer,
    Bose R; Ma CX
    N Engl J Med; 2021 Sep; 385(13):1241-1243. PubMed ID: 34551235
    [No Abstract]   [Full Text] [Related]  

  • 19. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.